Vyleesi Manufacturer Bridge Programs: How to Get Bremelanotide Cheaper in 2026

What Is Vyleesi and Why Does It Cost So Much?

Vyleesi (bremelanotide) is the second FDA-approved pharmacotherapy for hypoactive sexual desire disorder (HSDD) in premenopausal women, following flibanserin (Addyi). The FDA granted approval on June 21, 2019, under NDA 210557 after two Phase 3 RECONNECT trials demonstrated statistically significant improvements in desire and distress scores compared with placebo. [1][2]

The drug works as a melanocortin receptor agonist, binding MC1R and MC4R centrally to modulate dopaminergic and serotonergic pathways linked to sexual motivation. [3] Unlike flibanserin, bremelanotide is taken on demand (at least 45 minutes before anticipated sexual activity, no more than once in 24 hours), which appeals to patients who prefer situational rather than daily dosing.

Why the Price Is High

Specialty biologics and novel CNS drugs in small indication categories often carry high list prices because the addressable market is limited. HSDD affects an estimated 10% of premenopausal women in the United States. [4] Palatin Technologies spent more than a decade in clinical development before partnering with AMAG Pharmaceuticals for U.S. Commercialization.

Patients without manufacturer assistance routinely face co-pays of $300 to $500 per fill even with commercial insurance, and full list price near $800 to $900 per kit for the uninsured. [5]

Clinical Effectiveness Summary

The RECONNECT program enrolled 1,247 premenopausal women across two identical Phase 3 trials. In the pooled analysis, bremelanotide produced a statistically significant reduction in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score versus placebo (P<0.001) and a significant increase in satisfying sexual events. [1] The FDA's labeling acknowledges that the absolute mean differences were modest (approximately 0.3 to 0.5 points on a 4-point item scale), so shared decision-making between clinician and patient is standard practice before prescribing. [6]

How Manufacturer Bridge Programs Work

A manufacturer bridge program is a short-term benefit that covers prescription costs while a patient's insurance appeal is pending, while insurance authorization is being obtained, or during a defined introductory period. Bridge programs are distinct from long-term patient assistance programs (PAPs) and from co-pay savings cards, though the same manufacturer may run all three concurrently. [7]

The Vyleesi Savings Card (Commercial Insurance)

AMAG Pharmaceuticals (now part of Covis Pharma) has operated a co-pay savings card for commercially insured Vyleesi patients. Under the terms current as of early 2026:

• Eligible patients pay as little as $0 for the first fill.
• Subsequent fills are covered up to a stated monthly maximum, commonly $150 per fill.
• The annual maximum benefit cap has ranged from $1,800 to $3,600 depending on the program year.
• Patients must be 18 years or older, a resident of the United States or its territories, and enrolled in a commercial (non-government) health plan.

Medicare and Medicaid beneficiaries are explicitly excluded under federal anti-kickback regulations. [8] Patients on government plans must pursue separate routes (see below).

How to Enroll in the Savings Card

1. Obtain a valid prescription from a licensed U.S. Prescriber.
2. Visit the official Vyleesi website (vyleesi.com) or call the manufacturer's support line to download or activate the savings card.
3. Present the card at a participating retail or specialty pharmacy alongside the prescription.
4. The card adjudicates in real time; the pharmacist will confirm the final patient co-pay.

Enrollment is free. No income documentation is required for the co-pay card. Cards are not accepted at mail-order pharmacies that participate in federal programs, so confirm pharmacy eligibility before submitting. [9]

Bridge Supply During Prior Authorization

Some commercial insurers require prior authorization (PA) before covering Vyleesi, citing the modest effect sizes documented in RECONNECT trials. [1] If your insurer denies coverage or places the drug on a non-preferred tier, the manufacturer's patient support program can supply a bridge kit (typically one auto-injector unit) at no cost while the PA appeal is processed.

Contact the Vyleesi patient support line to initiate a bridge request. Your prescriber will need to provide:

• A diagnosis code confirming HSDD (ICD-10: F52.0, reduced sexual desire/interest).
• Documentation that the patient meets the FDA-approved indication (premenopausal, acquired, generalized disorder not attributable to another condition or medication). [6]
• Records showing prior therapies considered or tried, which strengthens the medical necessity argument. [10]

Patient Assistance Programs for Uninsured or Underinsured Patients

Patients who lack commercial insurance, or whose commercial plan excludes Vyleesi entirely, may qualify for a manufacturer PAP that provides the medication at no or nominal cost. [11]

Eligibility Criteria for PAPs

PAP income thresholds vary annually and by program design. Historically, programs for specialty drugs in this category have used 400% to 600% of the federal poverty level (FPL) as a cutoff, which for a single-person household in 2025 equates to roughly $60,240 to $90,360 annually. [12] These figures adjust each year with the FPL update published by the U.S. Department of Health and Human Services.

Required Documentation

• Completed PAP application form (available from the manufacturer or through a prescriber's office).
• Proof of income (most recent federal tax return or two recent pay stubs).
• Proof of insurance status (denial letter or statement of no coverage).
• Signed prescription from a licensed U.S. Prescriber.

Processing times have ranged from 5 to 15 business days in previous program years. Most PAPs ship directly to the prescriber's office rather than to the patient's home address.

The HealthRX Access Framework for Vyleesi (developed by our clinical pharmacist team) suggests a sequential approach: (1) verify commercial insurance tier and PA requirements before the first prescription is written; (2) enroll in the co-pay savings card on the same day the prescription is sent; (3) if PA is required, request a bridge supply immediately so there is no gap in access; (4) if income-eligible and uninsured, apply for the PAP in parallel rather than waiting for an insurance denial.

Third-Party Discount Programs and Pharmacy Coupons

Several third-party prescription discount services list Vyleesi, including GoodRx and NeedyMeds. Prices on these platforms fluctuate by pharmacy and zip code. As of late 2025, GoodRx-listed prices for bremelanotide have ranged from approximately $750 to $870 for a single auto-injector kit, which represents little to no savings below list price given the drug's limited generic competition. [13]

When Third-Party Coupons Are Actually Useful

Third-party coupons can be valuable in two narrow scenarios. First, if the manufacturer savings card has expired for the year (you have hit the annual cap) and the third-party price happens to undercut the insurance co-pay for that fill. Second, if your insurance plan's specialty co-pay tier is priced above the coupon price, though this is uncommon. Pharmacists are legally permitted to apply the lower of the two prices; ask explicitly.

Stacking Restrictions

Manufacturer savings cards generally prohibit stacking with other manufacturer-sponsored offers. Using a GoodRx coupon instead of the savings card is permitted, but using both simultaneously on a single claim is not. [14] Patients should calculate the net cost under each option at the time of each fill rather than assuming one is always cheaper.

HSA and FSA Eligibility for Vyleesi

Vyleesi qualifies as an HSA/FSA-eligible expense because it is a prescription drug dispensed for a diagnosed medical condition. [15] The IRS defines qualified medical expenses under Section 213(d) of the Internal Revenue Code, and prescription drugs by definition meet this standard regardless of the condition being treated. [16]

Practical Steps to Pay with HSA/FSA

• Confirm your HSA or FSA debit card is accepted at your pharmacy (most are).
• Keep the pharmacy receipt and the EOB from your insurer as documentation in case of an IRS audit.
• If your plan uses a benefits card that requires a prescription drug flag in the point-of-sale system, Vyleesi's NDC should trigger automatic approval; if declined, ask the pharmacist to resubmit with the correct drug category code.
• FSA funds are generally subject to a use-or-lose deadline (December 31 for most plans, or up to March 15 in a grace period). Timing your fill before year-end preserves those dollars.

Using an HSA or FSA does not affect eligibility for the manufacturer savings card; the two benefit streams are independent. [17]

Insurance Coverage Strategies: Getting Prior Authorization Approved

Bremelanotide carries a boxed warning about transient blood pressure increases, and it requires a specific patient population, so insurers frequently require PA documentation before covering it. The FDA label states that patients with high cardiovascular risk should not use the drug. [6] That restriction is part of what makes PA letters straightforward to write for appropriate candidates.

What a Strong PA Letter Includes

According to the Endocrine Society's clinical practice guideline on female sexual dysfunction, HSDD is a diagnosable condition with validated assessment tools including the Decreased Sexual Desire Screener (DSDS) and the FSFI. [18] A PA letter that cites a validated screening score, confirms the premenopausal status, rules out secondary causes (depression, relationship factors, medication-induced), and documents that non-pharmacologic options (sex therapy, psychotherapy) were considered carries significantly more weight than a generic request.

The Appeal Process

If a PA is denied on first submission, patients have the right to an internal appeal and, in most states, an external independent medical review. The Affordable Care Act requires most group health plans to offer at least one level of internal appeal. [19] The prescribing clinician should submit peer-reviewed clinical data from the RECONNECT trials [1] alongside the PA appeal to demonstrate that the clinical evidence supports the prescription.

Comparing Vyleesi to Flibanserin (Addyi) on Cost and Access

Flibanserin (Addyi), approved by the FDA in August 2015, is the only other FDA-approved drug for HSDD. [20] A generic flibanserin became available in the U.S. Market in 2019, which substantially reduced its cost relative to branded Addyi. Generic flibanserin 100 mg tablets are available at prices ranging from approximately $30 to $80 for a 30-day supply through discount platforms, versus the $800-range cost of branded Vyleesi.

The two drugs have different mechanisms, schedules, and side-effect profiles. Flibanserin requires daily dosing and carries a contraindication with alcohol; bremelanotide is on-demand but causes transient nausea in approximately 40% of patients in clinical trials and the noted blood pressure increase. [1][6] Neither drug outperforms the other on the validated efficacy endpoints by a margin large enough to constitute a clear superiority claim based on current trial data. [21]

For a patient primarily motivated by cost, the prescriber conversation should address whether flibanserin (particularly generic) is an appropriate first-line option before bremelanotide.

Telehealth Prescribing and Access Considerations

HSDD can be diagnosed and managed via telehealth in most U.S. States, which removes the barrier of needing an in-person gynecology or sexual medicine appointment. Telehealth prescribers must still confirm the diagnosis using validated tools, exclude secondary causes, and document shared decision-making per FDA labeling requirements. [6]

What Telehealth Platforms Can and Cannot Do

Telehealth providers can prescribe bremelanotide, enroll you in savings programs, submit PA letters, and coordinate pharmacy dispensing. They cannot bypass insurer coverage restrictions or federal exclusion rules for government plan beneficiaries. A prescriber who promises guaranteed low-cost access regardless of insurance status should be viewed with skepticism.

Specialty Pharmacy Considerations

Vyleesi is sometimes dispensed through specialty pharmacies rather than retail chains. Specialty pharmacy dispensing may affect whether a savings card applies. Before filling at a specialty pharmacy, confirm that the manufacturer savings card is accepted at that specific dispenser. AMAG's support line can provide a list of participating pharmacies. [9]

State and Federal Assistance for Government Plan Beneficiaries

Medicare Part D plans classify Vyleesi on formulary tiers that vary by plan. As of 2024, several Part D plans placed it on Tier 3 or Tier 4 with co-pays of $90 to $200 per fill after the deductible. [22] Medicare beneficiaries cannot use manufacturer co-pay cards, but they may qualify for the Extra Help (Low Income Subsidy) program administered by the Social Security Administration, which reduces Part D out-of-pocket costs for eligible enrollees. [23]

Medicaid coverage of Vyleesi varies by state. Some state Medicaid programs list it as a non-preferred drug requiring PA; others exclude it entirely. Patients on Medicaid should contact their state Medicaid pharmacy benefit manager directly for current formulary status.

The NeedyMeds database (needymeds.org) maintains updated PAP listings and state pharmaceutical assistance program (SPAP) information that can supplement federal coverage for low-income patients. [24]

Monitoring and Safety Considerations That Affect Access Planning

Before initiating bremelanotide, the FDA label requires a baseline blood pressure assessment. [6] The drug causes a mean maximum increase of approximately 6 mmHg in systolic and 3 mmHg in diastolic pressure in the first 12 hours post-dose, returning to baseline within 12 hours. [1] Patients with uncontrolled hypertension or known cardiovascular disease are excluded.

Nausea Management

Nausea is the most common adverse effect, reported in approximately 40% of clinical trial participants. [1] Pre-treatment with an oral antiemetic (e.g., ondansetron 4 mg approximately 30 minutes before bremelanotide injection) is a commonly employed clinical strategy, though this is an off-label use of ondansetron and should be discussed with the prescribing clinician. Adding an antiemetic prescription adds to the overall treatment cost and should be factored into access planning.

Hyperpigmentation

Bremelanotide activates MC1R, the melanocortin receptor also involved in pigmentation signaling. Focal hyperpigmentation of the face, gums, and breasts has been reported with repeated use. [3][6] The FDA label recommends against use in patients with dark skin tones if pigmentation change is a concern. This is worth discussing in the prescribing visit so that patients can make an informed choice.